Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study.

Ther Adv Neurol Disord · 2020 · PMC7222230 · PMID 32426038

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The exacerbation rate during eculizumab treatment in REGAIN and the OLE was reduced considerably from that in the year before REGAIN start and from that in the REGAIN placebo group, yet these differences did not reach statistical significance, probably owing to inadequate power with the small sample size.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.